Gilead Sciences, Inc. (NASDAQ:GILD)‘s stock had its “overweight” rating reissued by equities researchers at Barclays in a note issued to investors on Tuesday, Analyst Ratings Network.com reports.

Gilead Sciences (NASDAQ:GILD) traded down 2.34% during trading on Tuesday, hitting $87.53. 14,168,349 shares of the stock were exchanged. Gilead Sciences has a 52 week low of $86.00 and a 52 week high of $123.37. The firm has a market cap of $126.15 billion and a PE ratio of 8.04. The firm’s 50-day moving average is $97.87 and its 200 day moving average is $105.51.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, October 27th. The biopharmaceutical company reported $3.22 EPS for the quarter, topping analysts’ consensus estimates of $2.87 by $0.35. The business had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.84 billion. During the same quarter last year, the firm posted $1.84 EPS. Gilead Sciences’s revenue for the quarter was up 37.3% on a year-over-year basis. Analysts expect that Gilead Sciences will post $12.21 earnings per share for the current fiscal year.

In other Gilead Sciences news, CFO Robin L. Washington sold 6,250 shares of the stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $109.46, for a total transaction of $684,125.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Paul Rutherford Carter sold 2,000 shares of the stock in a transaction on Monday, January 4th. The shares were sold at an average price of $99.20, for a total transaction of $198,400.00. Following the sale, the executive vice president now directly owns 48,783 shares of the company’s stock, valued at approximately $4,839,273.60. The disclosure for this sale can be found here.

A number of large investors have recently made changes to their positions in GILD. Selz Capital purchased a new stake in shares of Gilead Sciences during the fourth quarter valued at $285,000. Proficio Capital Partners purchased a new stake in shares of Gilead Sciences during the fourth quarter valued at $26,000. Welch Group LLC boosted its stake in shares of Gilead Sciences by 10.8% in the fourth quarter. Welch Group LLC now owns 2,537 shares of the biopharmaceutical company’s stock valued at $257,000 after buying an additional 247 shares during the last quarter. Woodley Farra Manion Portfolio Management purchased a new stake in shares of Gilead Sciences during the fourth quarter valued at $259,000. Finally, Kistler-Tiffany Companies boosted its stake in shares of Gilead Sciences by 31.0% in the fourth quarter. Kistler-Tiffany Companies now owns 2,720 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 643 shares during the last quarter.

A number of other equities analysts also recently weighed in on the stock. Oppenheimer reissued a “buy” rating and set a $124.00 target price on shares of Gilead Sciences in a research note on Wednesday, October 28th. Maxim Group reissued a “buy” rating and set a $137.00 target price (up previously from $129.00) on shares of Gilead Sciences in a research note on Wednesday, October 28th. Morgan Stanley lifted their target price on shares of Gilead Sciences to $123.00 in a research note on Wednesday, October 28th. Cowen and Company reissued a “buy” rating and set a $130.00 target price (up previously from $125.00) on shares of Gilead Sciences in a research note on Wednesday, October 28th. Finally, Jefferies Group reaffirmed a “hold” rating and issued a $111.00 price target on shares of Gilead Sciences in a research note on Wednesday, October 28th. Eight analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $125.10.

Gilead Sciences, Inc. (NASDAQ:GILD), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

12 Month Chart for NASDAQ:GILD

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.